2020 ESMO . The latest cancer research developments from AstraZeneta, Mercer East and Roche are announced.

Recently, the European Society of Medical Oncology (ESMO) 2020 web conference is under way, the major pharmaceutical companies are sharing their latest cancer treatment progress.
Sina Pharmaceuticals, according to foreign media reports, selected an important research and development development, and shared with you: NO.1 AstraZene Imfinzi treatment of lung cancer AstraZeneta announced the anti-PD-L1 therapy Imfinzi treatment of non-small cell lung cancer (NSCLC) and extensive small cell lung cancer (ES-SCLC) 2 Phase III studies of the latest data.
-PACIFIC study: Non-excisive Phase III NSCLC patients who did not progress after receiving simultaneous radiotherapy (CRT) were assigned to Imfinzi or placebo therapy for a maximum duration of 1 year.
latest post-mortem analysis, Imfinzi shows the benefits of continuous total lifetime (OS) and progress-free lifetime (PFS).
, Imfinzi showed unprecedented survival rates in such patients, with nearly 50 percent surviving for four years.
the imfinzi group's four-year total survival rate is estimated at 49.6 per cent and the placebo group at 36.3 per cent.
47.5 months in the Imfinzi group and 29.1 months in the placebo group.
35.3 per cent for the imfinzi group and 19.5 per cent for the placebo group.
- CASPIAN Study: Conducted in ES-SCLC Patients.
new exploratory subgroup analysis data show that the proportion of patients in the Imfinzi plus chemotherapy group who survived and had no progression for 1 year (PFS -12 months) was more than three times (17% vs 4.5%) in the chemotherapy group.
all treatment groups, there was a 75% chance that patients in the subgroup who did not progress in the first year would survive in the second year.
patients in the subgroup who progressed in year 1 had only a 10% chance of survival in year 2.
the trial reached the main OS endpoint in 2019.
compared to chemotherapy, Imfinzi plus chemotherapy significantly reduced the risk of death by 27 percent.
no.2 Merca East 3 new cancer drugs - Vibostolimab is an anti-TIGIT therapy.
TIGIT is an immune checkpoint that, like PD-L1, acts as a "brake" to prevent T-cells from attacking tumors.
combining 2 drugs may have synergies.
data from the IB phase trial showed that the vibostolimab-Keytruda combination therapy was significant in patients with NSCLC who had not received PD-(L)1 therapy, tumor expression PD-L1, and tumor ratio score (TPS) of 1 percent.
in all patients in the group, the total remission rate (ORR) for combined therapy was 29%, PFS was 5.4 months, and the medium remission duration (DOR) had not yet been reached.
in patients with tumor expression PD-L1 and TPS of 1%, ORR was 46% and the medium PFS was 8.4 months.
in patients with tumor expression PD-L1 and TPS of 1%, ORR was 25% and the medium PFS was 4.1 months.
patients who received a PD-(L)1 checkpoint inhibitor showed significantly lower efficacy, but showed some combined drug benefits.
orR was 7% for vibostolimab monotherapy, 9 months for the medium DOR, 5% for the co-medication of vibostolimab and Keytruda, and 13 months for the medium DOR.
MK-4830 is an anti-ILT-4 therapy.
researchers are evaluating MK-4830 monotherapy and combining it with Keytruda in a variety of solid tumors.
released at the conference showed that MK-4830 was manageable and safe and showed signs of lasting remission in patients who had previously received multiple therapies.
the best remission was observed in patients who progressed after treatment with checkpoint inhibitors.
results showed that ORR was 24% of patients treated with MK-4830 and Keytruda.
all remissions occurred in patients who had previously received multiple therapies, including 5 patients who had previously received progression with anti-PD-(L)1 therapy (n=5/11).
patients received treatment for more than a year, and some are still receiving treatment.
- MK-6482 is a HIF-2 alpha inhibitor.
phase II study, published at the Conference, assessed the efficacy and safety of treating VHL-related renal cell carcinoma (RCC) and non-RCC tumors.
results showed that the best remission rates were observed in non-RCC tumors.
non-RCC tumor data: (1) in patients with pancreatic tumors (n-61), the confirmed ORR was 63.9%, including 4 cases of complete remission of 35 partial remissions.
(2) in patients with central nervous system hemangioblastoma (n-43), the confirmed ORR was 30.2%, including 5 cases of complete remission, 8 partial remissions, 65.1% of patients in stable condition.
(3) in patients with retinal tumors (n-16), 93.8% had improved or stable responses.
VHL-related RCC data: of the 61 patients, the confirmed ORR was 36.1%, all partially remission, and 38% were stable.
31.1 weeks from treatment to reaction, and the medium DOR has not yet been reached.
the target lesions decreased by 91.8% (n-56).
PFS has not yet been reached, with a one-year progress-free survival rate of 98.3%.
treatment duration was 68.7 weeks, with a minimum follow-up of 60 weeks, and 91.8% of patients were still receiving treatment.
NO.3 Roche's treatment of prostate cancer Roche has published the results of the early top line of clinical studies in phase III clinical studies of ipasertib first-line therapeutic metastatic degenerative prostate cancer (mCRPC), which showed that the primary endpoint of radiology progression-free survival (rPFS) was achieved in patients with mCRPC who lost the function of anti-cancer protein PTEN in tumors.
specific data were: (1) in patients identified as missing PTEN by immunogastasic analysis, the medium rPFS for ipatasertib-Zytiga therapy was 18.5 months and Zytiga was 16.5 months (HR=0.77; p=0.0335).
(2) rPFS was more different in patients identified as missing in the next generation of sequencing, with the medium rPFS treated with ipatasertib-Zytiga at 19.1 months and Zytiga at 14.2 months, accounting for less than one-fifth of the 1101 patients in the study.
In the broader group of intentional therapy (ITT) patients, the medium rPFS of the ipatasertib-Zytiga combination was 19.2 months, higher in value than in patients with PETN deficiency, but the middle rPFS in the Zytiga group reached 16.6 months, resulting in a poorer statistical performance (HR=0.84, p=0.0431).
secondary endpoints, ipatasertib-Zytiga performed fairly well in patients with PTEN deficiency and ITT, with a medium time of 12.6 months and 12.9 months for PSA progression, respectively, and Zytiga for about 8 months in both categories of patients.
addition, ipatasertib-Zytiga was 61% ORR in class 2 patients.
these results confirm the therapeutic potential of ipasertib in patients with PETN missing mCRPC.
it is worth noting that at the ESMO meeting, Roche also published data on patients with genotype breast cancer, showing that there was no significant effect of adding ipasertib to yew alcohol: the middle PFS, ORR, and DOR in the ipatasertib-yew alcohol group were all the same.
the results questioned the idea that "tumor patients with PIK3CA/AKT1/PTEN changes are the best target population for ipasertib."
.4 Pfizer Lorbrena's treatment of lung cancer ALK-positive NSCLC is a nib market with a wide range of targeted drugs to choose from.
The meeting, Pfizer presented positive results from the next generation of ALK inhibitor Lorbrena's first-line treatment CROWN study, which was impressive and had very competitive remission rates, particularly in intracranial tumors: intracranial ORR was 82%, and intracranial disease progression time HR reached a staggering 0.07 (equivalent to a 93% reduction in the risk of intracranial disease progression).
, the mid-PFS has not yet been reached.
in horizontal comparisons, Lorbrena is still the best.
, however, compared to other ALK inhibitors, Lorbrena showed toxic characteristics of neurocognitive disorders, which may be explained by the drug's high brain permeability, including mood changes and impaired attention.
could put Lorbrena at a disadvantage in the first-line treatment competition.
the drug sequencing still seems to be an open question or requires further head-to-head clinical trials until more biomarkers are found to predict treatment responses.
to treat breast cancer with No.5 Lilly/Pfizer CDK4/6 inhibitors It is important to select the right people for the drug.
2 CDK4/6 inhibitors (Lilly Verzenio and Pfizer Ibrace) to assist in the treatment of breast cancer Phase 3 clinical data.
results were very different, with success in the MonarchE study showing a 25 percent reduction in the risk of recurrence, and failure in the PALAS study showing total ineffectiveness.
two studies evaluated the most common patients with HR-/HER2-early breast cancer with the aim of adding CDK4/6 inhibitors to complementary endocrine therapy to prevent or delay recurrence.
surgery, chemotherapy, radiotherapy, hormone-assisted therapy, which can be applied for up to 10 years and cure most patients, but still 30% relapse. the
monarchE study used clinical and pathological risk factors (e.g., lymph nodes, tumor size) to ensure that patients with a very high risk of recurrence were included;
two studies tested Verzenio or Ibrace for 2 years on the basis of standard assisted endocrine therapy, with non-invasive disease lifetime (iDFS) as the primary endpoint.
results showed that the survival curve of the monarchE study showed early, clear separation: for 15 months of medium follow-up, Verzenio and control groups had 2-year estimates of iDFS rates of 92.2% and 88.7%, respectively, and there were statistical differences, equivalent to a 25.3% reduction in the risk of cancer recurrence within 2 years, mainly to prevent metastasis to the bones and liver.
overall, the risk of cancer recurrence at a distance was reduced by 28.3% (p-0.0085).
the survival curve of the PALAS study showed little difference: the ibrance and control groups iDFS rates were 88.2% and 88.5%, respectively, with no difference in secondary endpoints for 23.7 months of middle follow-up.
notable, up to 42 percent of patients in the Ibrance group withdrew from treatment for side effects, compared with 16.6 percent in the MonarchE study, and only 5 percent stopped treatment for diarrhea, which is considered Verzenio's most disturbing side effect.
two drugs are considered to be the same in the treatment of metastasis.
but because Ibrace missed targets in complementary treatments, seller analysts have cut 2 billion sales for 2026 from $8 billion to more than $50 this year, according to a consensus forecast by Evaluate Pharma.
Verzenio enters the transfer market four years after Ibrox, the success of complementary therapy will lead to a large new patient population and the emergence of similar competitors, with sales expected to reach $3.7 billion in 2026.
source: 1, Imfinzi expressed never survival in unresectable, Stage III non-small cell lung cancer with an #ESMO20 50% of patients surviving four years 2, #ESMO20: It's not just Just Keytruda anymore - Merck Spotlights 3 top early-stage cancer drugs 3, ESMO: Roche's Akt resedor scores slight win over J and J's Zytiga 4, Esmo 2020 - Pfizer's next-gen cancer drug drug impresses. 5, Esmo 2020 - Lilly's latecomer scores in early breast cancer.